Should the hematocrit (hemoglobin) be normalized in pre-ESRD or dialysis patients? Yes!

被引：14

作者：

Besarab, A ^{[1
]}

Aslam, MA ^{[1
]}

机构：

[1] W Virginia Univ, Sch Med, Dept Med, Div Nephrol,Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA

来源：

BLOOD PURIFICATION | 2001年 / 19卷 / 02期

关键词：

D O I：

10.1159/000046935

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：168 / 174

页数：7

共 60 条

[1]

Amann K, 1998, J AM SOC NEPHROL, V9, P1018

[2] Reduced cardiac ischaemia tolerance in uraemia - What is the role of structural abnormalities of the heart? [J].

Amann, K ;

Ritz, E .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (07) :1238-1241

[3]

AMANN K, 1997, ACTUALITES NEPHROLOG, P1

[4]

Barany P, 1996, J AM SOC NEPHROL, V7, pA1117

[5]

BARANY P, 1998, J AM SOC NEPHROL, V9, pA1234

[6] Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease [J].

Berns, JS ;

Rudnick, MR ;

Cohen, RM ;

Bower, JD ;

Wood, BC .

KIDNEY INTERNATIONAL, 1999, 56 (01) :253-260

[7]

Besarab A, 1995, Curr Opin Nephrol Hypertens, V4, P155, DOI 10.1097/00041552-199503000-00008

[8] A study of parenteral iron regimens in hemodialysis patients [J].

Besarab, A ;

Kaiser, JW ;

Frinak, S .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (01) :21-28

[9] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].

Besarab, A ;

Bolton, WK ;

Browne, JK ;

Egrie, JC ;

Nissenson, AR ;

Okamoto, DM ;

Schwab, SJ ;

Goodkin, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590

[10]

Besarab A, 1993, ASAIO J, V39, P11

← 1 2 3 4 5 6 →